Acrivon Therapeutics, Inc. Common Stock (ACRV) vs ImmuCell Corporation (ICCC)
A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and ImmuCell Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
ACRV
Acrivon Therapeutics, Inc. Common Stock
$1.92HealthcareDelayed quote: Oct 6, 2026, 12:54 PM EDT
ICCC
ImmuCell Corporation
$9.78HealthcareDelayed quote: Oct 6, 2026, 12:44 PM EDT
Total return — ACRV vs ICCC
growth of $100 · dividends reinvested · last 4yACRV -88.1% (-41.3%/yr)ICCC +31.9% (+7.2%/yr)ICCC compounded faster over this window
Log scale — wide-divergence pair
ACRV ICCC
ACRV vs ICCC: by the numbers
- •ICCC is the larger company ($88M vs $82M market cap).
- •ICCC is profitable (2.57% net margin) while ACRV runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | ACRV | ICCC |
|---|---|---|
| P/E ratio | N/A | 115.60 |
| P/S ratio | N/A | 2.88 |
| P/B ratio | 0.95 | 2.82 |
| EV / EBITDA | N/A | 14.73 |
| FCF yield | N/A | 4.76% |
Profitability
| Metric | ACRV | ICCC |
|---|---|---|
| Gross margin | 0.00% | 40.32% |
| Operating margin | 0.00% | 12.60% |
| Net margin | 0.00% | 2.57% |
| ROE | -85.65% | 2.51% |
| ROIC | -88.28% | 8.16% |
Growth (annualized)
| Metric | ACRV | ICCC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 13.74% |
| Total return CAGR (5Y) | N/A | 0.65% |
Frequently asked
- Is ACRV or ICCC more profitable?
- ICCC runs the higher net margin — ACRV at 0.00% versus ICCC at 2.57%.
Go deeper
Dig into the metrics
ImmuCell P/E ratioAcrivon Therapeutics, Inc. Common Stock ROEImmuCell ROEAcrivon Therapeutics, Inc. Common Stock operating marginImmuCell operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthImmuCell revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowImmuCell free cash flow
Acrivon Therapeutics, Inc. Common Stock & ImmuCell appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.